The selective cannabinoid antagonist SR 141716A blocks cannabinoid- induced antinociception in rats

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 1-2, 1997, Pages 7-12

  Lichtman, Aron H ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9 tetrahydrocannabinol ( 9 THC); Antinociception; C annabinoid; Cannabis; Catalepsy; CP 55,940; Intracerebroventicular; Marijuana; Morphine; SR 141716A

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABIS; CYCLIC GMP; MORPHINE; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CATALEPSY; DRUG ANTAGONISM; HYPOTENSION; HYPOTHERMIA; MEMORY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STATISTICAL ANALYSIS; TAIL FLICK TEST; WITHDRAWAL REFLEX;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; CANNABINOIDS; CATALEPSY; CYCLOHEXANOLS; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MALE; MORPHINE; PAIN; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL;

ANIMALIA; CANNABIS; CANNABIS SATIVA;

EID: 0030944030     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00121-9     Document Type: Article

References (40)

1. Aceto, M.D.; Scates, S.M.; Lowe, J.A.; Martin, B.R. Cannabinoid precipitated withdrawal by the selective cannabinoid antagonist, SR 141716A. Eur. J. Pharmacol. 282:R1-R2; 1995.
2. Bodnar, R. J.; Paul, D.; Rosenblum, M.; Liu, L.; Pasternak, G. W. Blockade of morphine analgesia by both pertussis and cholera toxins in the periaqueductal gray and locus coeruleus. Brain Res. 529:324-328; 1990.
3. Brown, A. M.; Birnbaumer, L. Ionic channels and their regulation by G protein subunits. Ann. Rev. Physiol. 52:197-213; 1990.
4. Collins, D. R.; Pertwee, R. G.; Davies, S. N. Prevention by the cannabinoid antagonist, SR 141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115:869-870; 1995.
5. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:586-594; 1996.
6. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:74-79; 1941.
7. Dewey, W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38:151-178; 1986.
8. Ferri, S.; Cavicchini, E.; Romualdi, P.; Speroni, E.; Murari, G. Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology (Berlin) 89:244-247; 1986.
9. Lichtman, A. H.; Cook, S. A.; Martin, B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:585-593; 1996.
10. Lichtman, A. H.; Dimen, K. R.; Martin, B. R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119:282-290; 1995.
11. Lichtman, A. H.; Martin, B. R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:517-523; 1991.
12. 2 noradrenergic mechanism. Brain Res. 559:309-314; 1991.
13. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126:125-131; 1996.
14. Lichtman, A. H.; Smith, P. B.; Martin, B. R. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain 51:19-26; 1992.
15. Martin, B. R. Characterization of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice. In: Harvey, D. J., ed. Marihuana '84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press; 1985:685-692.
16. Martin, B. R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:45-74; 1986.
17. Martin, B. R.; Prescott, W. R.; Zhu, M. Quantitation of rodent catalepsy by a computer-imaging technique. Pharmacol. Biochem. Behav. 43:381-386; 1992.
18. Martin, W. J.; Lsi, N. K.; Patrick, S. L.; Tsou, K.; Walker, J. M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629:300-304; 1993.
19. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564; 1990.
20. Mountjoy, K. G.; Robbins, L. S.; Mortrud, M. T.; Cone, R. D. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248-1251; 1992.
21. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65; 1993.
22. Noyes, J. R.; Brunk, S. F.; A very, D. H.; Canter, A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18:84-89; 1975.
23. Parenti, M.; Tirone, F.; Giagnoni, G.; Pecora, N.; Parolaro, D. Pertussis toxin inhibits the antinociceptive action of morphine in the rat. Eur. J. Pharmacol. 124:357-359; 1986.
24. Paxinos, G.; Watson, C.; The rat brain in stereotaxic coordinates. 2nd ed. Australia: Academic Press; 1986.
25. Pertwee, R. G. The ring test: A quantitative method for assessing the "cataleptic" effect of cannabis in mice. Br. J. Pharmacol. 46:753-163; 1972.
26. Przewlocki, R.; Costa, T.; Lang, J.; Herz, A. Pertussis toxin abolishes the antinociception mediated by opioid receptors in rat spinal cord. Eur. J. Pharmacol. 144:91-95; 1987.
27. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Alonso, R.;Congy, C.; Soubrié, P.; Brelière, J. C.; Le Fur, G. Biochemical and pharmacological characterization of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1941-1947; 1995.
28. Rinaldi-Carmona, M., Earth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., Ferrara, P., Soubrié, P., Brelière, J. C., and Le Fur, G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240-244; 1994.
29. Souilhac, J.; Poncelet, M.; Rinaldi-Carmona, M.; Fur, G. L.; Soubrié, P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51:3-7; 1995.
30. Tallarida, R. J.; Murray, R. B.; Manual of pharmacological calculations with computer programs. 2nd ed. New York: Springer-Verlag; 1987:26-31.
31. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280: R13-R15; 1995.
32. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278:279-283; 1995.
33. Welch, S. P.; Thomas, C.; Patrick, G. S. Modulation of cannabinoid-induced antinociception following intracerebroventricular vs. intrathecal administration to mice: Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:310-321; 1995.
34. Wiley, J. L.; Barrett, R. L.; Lowe, J.; Balster, R. L.; Martin, B. R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676; 1995.
35. 9-THC in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1-6; 1995.
36. Yaksh, T. L. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in periaqueductal gray. Brain Res. 160:180-185; 1979.
37. Yaksh, T. L. The antincociceptive effects of intrathecally administered levonantradoland desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:3348-3408; 1981.
38. Yaksh, T. L.; Rudy, T. A. Studies on the direct spinal action of narcotics in the production of analgesia in the rat. J. Pharmacol. Exp. Ther. 202:411-428; 1977.
39. Yaksh, T. L.; Yeung, J. C.; Rudy, T. A. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: Observation of differential effects within the periaqueductal gray. Brain Res. 114:83-103; 1976.
40. Yeung, J. C.; Rudy, T. A. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J. Pharmacol. Exp. Ther. 215:633-642; 1980.